Article

About Our Sponsor: VIGAMOX™ (moxifloxacin HCl ophthalmic solution)

VIGAMOX™ (moxifloxacin HCl ophthalmic solution) 0.5% as base is theonly FDA-approved fluoroquinolone drop that offers the following featuresand benefits: VIGAMOX™ solution is the only fourth generation fluoroquinolone eye-drop formulated at a 0.5% concentration, providing higher drug concentration throughout the relevant ocular structures.1 Formulated at a pH of 6.8, the near-neutral pH of VIGAMOX™ solution translates directly into excellent comfort, tolerability and increased solubility.1 VIGAMOX™ solution is robust enough to not only meet, but exceed all United States Pharmacopoeia (USP) tests without the need for benzalkonium chloride: this is a direct result of the inherent anti-bacterial andanti-fungal activity of the moxifloxacin formulation itself.2 The active ingredient of VIGAMOX™, solution moxifloxacin, is the only available fluoroquinolone with a bicyclic side-chain at the C-7 position: this reduces the ability of the microbial cell's efflux pump to flush out antibiotic, thus increasing the drug's length of stay in the microorganism, leading to improved efficacy and further inhibition of resistance.1 These unique product attributes speak directly to the benefits that VIGAMOX™ solution brings to ophthalmologists and patients. Please see prescribinginformation at www.vigamox.com.1Alfonso EC, Katz HR, McCulley JP, O'Brien TP. Moxifloxacin 0.5%: a4th generation ocular fluoroquinolone. Excerpts from RefractiveEyecare for Ophthalmologists. March 2003; 7 (suppl):202Moxifloxacin: Antimicrobial efficacy test results. Data on file, AlconLaboratories, Inc.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) NeuroOp Guru: Using OCT to forecast outcomes in ethambutol optic neuropathy
(Image credit: Ophthalmology Times) Inside NYEE’s new refractive solutions center with Kira Manusis, MD
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD
(Image credit: Ophthalmology Times) Structure-function correlates using high-res OCT images with Karl Csaky, MD, PhD
(Image credit: Ophthalmology Times) SriniVas Sadda, MD, on high-res OCT of atrophic and precursor lesions in AMD
(Image credit: Ophthalmology Times) Christine Curcio, PhD, shares histology update supporting review software and revised nomenclature for <3 μm OCT
© 2025 MJH Life Sciences

All rights reserved.